Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study

BMC Cardiovascular Disorders

Karin Martin-Latry³  Bernard Bégaud¹  Thierry Couffinhal³  Bernard Dedieu²  Mathieu Molimard¹  Philippe Latry² 

[1] U 657, INSERM, Bordeaux, (33000), France;Direction Régionale du Service Médical de l'Assurance Maladie d'Aquitaine, Cnam-TS, Bordeaux, (33000), France;U 1034, INSERM, Pessac, (33600), France

关键词: Insurance, Health, Reimbursement;    Pharmacoepidemiology;    Databases, Factual;    Medication adherence;    Risk factors;    Hydroxymethylglutaryl-CoA Reductase Inhibitors;   

Others  :  1085784
DOI  :  10.1186/1471-2261-11-46

 received in 2011-01-12, accepted in 2011-07-26,  发布年份 2011

【 摘 要 】

Background

While the factors for poor adherence for treatment with statins have been highlighted, the impact of their combination on adherence is not clear.

Aims

To estimate adherence for statins and whether it differs according to the number of cardiovascular risk factors.

Methods

A cohort study was conducted using data from the main French national health insurance system reimbursement database. Newly treated patients with statins between September 1 and December 31, 2004 were included. Patients were followed up 15 months. The cohort was split into three groups according to their number of additional cardiovascular risk factors that included age and gender, diabetes mellitus and cardiovascular disease (using co-medications as a proxy). Adherence was assessed for each group by using four parameters: (i) proportion of days covered by statins, (ii) regularity of the treatment over time, (iii) persistence, and (iv) the refill delay.

Results

16,397 newly treated patients were identified. Of these statin users, 21.7% did not have additional cardiovascular risk factors. Thirty-one percent had two cardiovascular risk factors and 47% had at least three risk factors. All the parameters showed a sub-optimal adherence whatever the group: days covered ranged from 56% to 72%, regularity ranged from 23% to 33% and persistence ranged from 44% to 59%, but adherence was better for those with a higher number of cardiovascular risk factors.

Conclusions

The results confirm that long-term drug treatments are a difficult challenge, particularly in patients at lower risk and invite to the development of therapeutic education.

【 授权许可】

   
2011 Latry et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Baigent C, Keech A, Kearney P, Blackwell L, Buck G, C P, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Collaborators CTTC: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278.
• [2]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S) Lancet 1994, 344(8934):1383-1389.
• [3]Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361(9364):1149-1158.
• [4]Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360(9346):1623-1630.
• [5]Shepherd J, Cobbe S, Ford I, Isles C, Lorimer A, Macfarlane P, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333(20):1301-1307.
• [6]Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335(14):1001-1009.
• [7]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 1998, 339(19):1349-1357.
• [8]Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Jama 1998, 279(20):1615-1622.
• [9]Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364(9435):685-696.
• [10]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002, 360(9326):7-22.
• [11]Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. Jama 2002, 287(24):3215-3222.
• [12]Wei L, Ebrahim S, Bartlett P, Davey P, Sullivan FM, MacDonald TM: Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005, 330(7495):821.
• [13]Wieringa N, De Graeff P, Van der Werf G, Vos R: Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use. Eur J Clin Pharmacol 1999, 55:537-544.
• [14]Martin K, Begaud B, Latry P, Miremont-Salame G, Fourrier A, Moore N: Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004, 57(1):86-92.
• [15]Abraha I, Montedori A, Stracci F, Rossi M, Romagnoli C: Statin compliance in the Umbrian population. Eur J Clin Pharmacol 2003, 59(8-9):659-661.
• [16]Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J: Persistence of use of lipid-lowering medications: a cross-national study. Jama 1998, 279(18):1458-1462.
• [17]Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term persistence in use of statin therapy in elderly patients. Jama 2002, 288(4):455-461.
• [18]Caspard H, Chan A, Walker A: Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005, 27(10):1639-1646.
• [19]Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, Chinellato A: Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 2007, 63(2):197-203.
• [20]Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT: Long-term adherence to statin treatment in diabetes. Diabet Med 2008, 25(7):850-855.
• [21]Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB: Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004, 164(21):2343-2348.
• [22]Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J: Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005, 59(5):564-573.
• [23]Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D, Gaddi A, Vaccheri A, Montanaro N: Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 2008, 64(4):425-432.
• [24]Poluzzi E, Strahinja P, Vaccheri A, Vargiu A, Silvani MC, Motola D, Marchesini G, De Ponti F, Montanaro N: Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. Br J Clin Pharmacol 2007, 63(3):346-355.
• [25][http://www.insee.fr] webcite Last access: 2009, February, 18th
• [26][http://www.who.int/classifications/atcddd/en/] webcite Last access: 2009, February, 18th
• [27]Steiner JF, Gardner EM: Assessing medication adherence from pharmacy records. Pharmacoepidemiol Drug Saf 2006, 15(8):575-577.
• [28]Andrade SE, Kahler KH, Frech F, Chan KA: Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006, 15(8):565-574.
• [29]Hudson M, Rahme E, Richard H, Pilote L: Comparison of measures of medication persistency using a prescription drug database. Am Heart J 2007, 153(1):59-65.
• [30]Steiner JF, Koepsell TD, Fihn SD, Inui TS: A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988, 26(8):814-823.
• [31]Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods, validity and applications. J Clin Epidemiol 1997, 30(1):105-116.
• [32]Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS: Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006, 44(5):471-477.
• [33]Hess LM, Raebel MA, Conner DA, Malone DC: Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006, 40(7-8):1280-1288.
• [34]Bourgault C, Sénécal M, Brisson M, Marentette M, Grégoire J: Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005, 19(8):607-613.
• [35]Becker MH, Maiman LA: Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975, 13(1):10-24.
• [36]Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Jama 2002, 288(4):462-467.
• [37]Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G: The rational clinical examination. Is this patient taking the treatment as prescribed? Jama 1993, 269(21):2779-2781.
• [38]Catalan VS, LeLorier J: Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000, 3(6):417-426.
• [39]Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM: Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007, 28(2):154-159.
• [40]Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM: Long term persistence with statin treatment in daily medical practice. Heart 2004, 90(9):1065-1066.
• [41]Lachaine J, Rinfret S, Merikle EP, Tarride JE: Persistence and adherence to cholesterol lowering agents: evidence from Regie de l'Assurance Maladie du Quebec data. Am Heart J 2006, 152(1):164-169.
• [42]Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P, Sorensen R, Folke F, Gadsboll N, Rasmussen S, Kober L, Madsen M, Torp-Pedersen C: Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007, 116(7):737-744.
• [43]McGinnis B, Olson KL, Magid D, Bayliss E, Korner EJ, Brand DW, Steiner JF: Factors related to adherence to statin therapy. Ann Pharmacother 2007, 41(11):1805-1811.
• [44]Evans JM, MacDonald TM: Record-linkage for pharmacovigilance in Scotland. Br J Clin Pharmacol 1999, 47(1):105-110.
• [45]Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E: Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 2009, 47(3):334-341.